Fig. 8From: Identification of a novel m6A-related lncRNAs signature and immunotherapeutic drug sensitivity in pancreatic adenocarcinomaIC50 of different immunotherapy drugs according to distinct risk score. (A) (5Z)-7-Oxozeaenol, (B) ATRA, (C) EHT 1864, (D) GDC0449, (E) Phenformin, (F) JNJ-26,854,165, (G) TW 37, (H) 17-AAG were more sensitive in the high-risk groups. (I) LY317615, (J) PD-0325901, (K) Pyrimethamine, (L) VX-11e were more sensitive in the low-risk groupsBack to article page